IGHE and Alzheimer disease: However, from the clinical results of treatment with dupilumab and omalizumab for both recalcitrant AD and CU, it has become clear that the key pathogenesis of AD is mediated by Th2 cells through the IL-4 and IL-13 pathways and that the pathogenesis of CU involves IgE-mediated histamine release.